Cargando...
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...
Guardado en:
| Publicado en: | Cancers (Basel) |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827355/ https://ncbi.nlm.nih.gov/pubmed/31547040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101404 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|